- Letter to the Editor
- Open Access
- Published:
Tumor necrosis factor inhibitors for pediatric patients with SAPHO syndrome associated with acne conglobata
Pediatric Rheumatology volume 20, Article number: 88 (2022)
Abstract
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease with osteoarticular and cutaneous involvements as its main manifestations. Acne conglobata as a severe acne form may affect adolescent patients. Tumor necrosis factor inhibitors are usually used as a second-line therapy for refractory SAPHO syndrome and has been reported to treat acne conglobata successfully. We herein report three cases of adolescent patients with SAPHO syndrome associated with acne conglobata who were successfully treated with TNFi therapy.
Dear editor:
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic autoinflammatory disease with osteoarticular and dermatological involvement. Palmoplantar pustulosis and severe acne are the most common types of cutaneous manifestations. As a severe form of nodular acne vulgaris, acne conglobata usually presents with deep burrowing abscesses interconnected with each other and primarily affects adolescent boys with SAPHO syndrome. If not treated timely, acne conglobata may cause disfiguring scars [1]. Tumor necrosis factor inhibitors (TNFi) have been used as a second-line therapy to treat refractory SAPHO syndrome [2]. Moreover, case reports have also recorded improvement of acne conglobata in response to TNFi [3]. Herein, we report three cases of adolescent patients with SAPHO syndrome associated with acne conglobata who were successfully treated with TNFi therapy.
These patients’ baseline data were gathered before and during a 12-week followed-up (Table 1). All the patients and their legal guardians have signed the written informed consents. Before the follow-up, These patients were treated with NSAIDs or other therapies before but didn’t show significant disease remission. Two patients were treated with TNFi before and gained good efficacy, but acne conglobata and osteoarticular pain worsened quickly after reducing the dosage.
After 12 weeks of TNFi treatment, the acne conglobata condition improved (Supplementary Figs. 1, 2 and 3). The clinical scores and laboratory indexes decreased significantly (Fig. 1), indicating the alleviation of manifestations and inflammatory condition, especially in case 3. Patient 2 and patient 3’s osteoarticular involvements were more extensive at the beginning. They were reported to have released anterior chest wall and hip joints pain, in addition to the significantly declined clinical scores. In terms of adverse events, none were observed other than increased uric acid. Although the pathogenesis of SAPHO syndrome remains unclear, there is a theory that proinflammatory cytokines such as IL-8 and TNF-α can be triggered by Cutibacterium acnes infection, leading to skin lesion such as acne conglobata as well as a systemic inflammatory response [4]. Commonly used TNF-α antagonists include infliximab, etanercept and adalimumab, all of which have been reported to successfully alleviate SAPHO syndrome [5]. To our knowledge there are no other case series describing the efficacy of TNF α antagonists treatment for patients with acne conglobate in SAPHO syndrome. Interestingly, Su et al. found in a 42-year-old male patient with SAPHO syndrome that after treatment with etanercept, bone and joint lesions were improved like the 3 patients in this case series, while skin lesions were not significantly alleviated, possibly because TNFi could not treat the permanent damage of hair follicular in acne aggregata [6]. Therefore, TNFi treatment for SAPHO should be considered earlier on in the disease and continued to maintain remission. For the safety profile, hyperuricemia was observed in two patients. This is not a known adverse event for TNFi and has not been reported in patients with SAPHO. The specific relation between hyperuricemia and the treatment is unclear, and the safety of TNFi treatment still needs to be verified by large-scale clinical trials. It is a descriptive observation with small sample size and short follow-up period, but the results are promising and should encourage further study to confirm the efficacy and safety profile. Overall, long-term TNFi therapy has the potential to be a favorable option for adolescent SAPHO syndrome patients with acne conglobata.
Availability of data and materials
All data generated or analysed during this study are included in this published article.
Abbreviations
- SAPHO:
-
Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis
- TNFi:
-
Tumor necrosis factor inhibitors
- NSAIDs:
-
Nonsteroidal anti-inflammatory drugs
- TGP:
-
Total glycosides of paeony
- SASP:
-
Salicylazosulfapyridine
- BPs:
-
Bisphosphonates
- VAS:
-
Visual Analog Scale
- BASDI:
-
Bath Ankylosing Spondylitis Disease Activity Index
- BASFI:
-
Bath Ankylosing Spondylitis Functional Index
- ASDAS:
-
Ankylosing Spondylitis Disease Activity Score
- HAQ-S:
-
Health Assessment Questionnaire for the Spondylarthropathties
- DLQI:
-
Dermatology Life Quality Index
References
Hafsi W, Badri T. Acne Conglobata. In: StatPearls. Treasure Island: StatPearls Publishing; 2021.
Rukavina I. SAPHO syndrome: a review. J Child Orthop. 2015;9(1):19–27. https://doi.org/10.1007/s11832-014-0627-7.
Sand FL, Thomsen SF. Adalimumab for the treatment of refractory acne conglobata. JAMA Dermatol. 2013;149(11):1306–7. https://doi.org/10.1001/jamadermatol.2013.6678.
Zimmermann P, Curtis N. The role of Cutibacterium acnes in auto-inflammatory bone disorders. Eur J Pediatr. 2019;178(1):89–95. https://doi.org/10.1007/s00431-018-3263-2.
Daoussis D, Konstantopoulou G, Kraniotis P, Sakkas L, Liossis SN. Biologics in SAPHO syndrome: a systematic review. Semin Arthritis Rheum. 2019;48(4):618–25. https://doi.org/10.1016/j.semarthrit.2018.04.003.
Su YS, Chang CH. SAPHO syndrome associated with acne conglobata successfully treated with etanercept. J Formos Med Assoc. 2015;114(6):562–4. https://doi.org/10.1016/j.jfma.2013.10.001.
Acknowledgements
Not applicable.
Funding
This work was supported by the National Natural Science Foundation of China (No.82074246 to CL) for data collection.
Author information
Authors and Affiliations
Contributions
SL, XW and YC designed the case series report and were major contributors in writing the manuscript. ZL, YL, MM and CL helped in data collection and analysis. The authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
All the patients and their legal guardians have signed the written informed consents.
Competing interests
The authors have no conflicts of interest to declare.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1: Supplementary Figure 1.
Skin lesions of patient 1 before (A) and after (B) the 12-week TNFi treatment. The severe acne characterized by cyst nodules and abscesses in the cheeks improved after the treatment. The area of the acne shrank.
Additional file 2: Supplementary Figure 2.
Skin lesions of patient 2 before (A) and after (B) the 12-week TNFi treatment. The severe acne characterized by cyst nodules and abscesses in the forehead and nose improved after the treatment, left only some slight scar formation.
Additional file 3: Supplementary Figure 3.
Skin lesions of patient 3 before (A) and after (B) the 12-week TNFi treatment. The severe acne characterized by cyst nodules and abscesses in the forehead, nose and cheeks improved after the treatment, left only some superficial scar formation.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Liu, S., Wu, X., Cao, Y. et al. Tumor necrosis factor inhibitors for pediatric patients with SAPHO syndrome associated with acne conglobata. Pediatr Rheumatol 20, 88 (2022). https://doi.org/10.1186/s12969-022-00749-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12969-022-00749-9
Keywords
- Acne conglobata
- Tumor necrosis factor inhibitor
- SAPHO syndrome